Table 1 Summary of research projects proposed by the ART panel
From: Report of the first AKI Round Table meeting: an initiative of the ESICM AKI Section
Epidemiology of AKI | Medical therapy of AKI | Continuous renal replacement therapy | |
|---|---|---|---|
Main research question | What is the epidemiology of critically ill patients with AKI of different durations? | Is a higher target MAP in critically ill patients with pre-existing hypertension renoprotective? | What is the difference in large molecule clearance between convection versus diffusion? |
Systematic review of literature | AKI prevalence | Role of higher MAP for patients with hypertension at risk of development or progression of AKI | Solute clearance in CVVH vs CVVHD |
Cohort study | Retrospective cohort | – | International survey |
RCT | – | ||
Target group | Hypertensive adult patients admitted to ICU | Patients on CRRT | |
Intervention group | Target MAP 80–90 mmHg for at least 48 hours after randomization | treatment with CVVH | |
Comparator | Target MAP 65-75 mmHg for at least 48 hours after randomization | Treatment with CVVHD | |
Primary outcome | In patients without AKI at randomization: Primary outcome: prevention of AKI in 7 days In patients with AKI and no need for RRT at randomization: Primary outcome: MAKE at 28 days | Clearance of beta 2 microglobulin | |
Sample size calculation | Hypothesis 1: Expecting 40% of MAKE 30 in patients with AKI in the control group and a 10% absolute decrease in the risk (ie. 30% of MAKE 30 in intervention group) Target: 182 patients per group (alpha risk 5%, power 80%) Target: 240 patients per group (alpha risk 5%, power 90%) Hypothesis 2: Expecting 40% of MAKE 30 in patients with AKI in the control group and a 5% absolute decrease in the risk (ie 35% of MAKE 30 in intervention group) Target: 742 patients per group (alpha risk 5%, power 80%) Target: 988 patients per group (alpha risk 5%, power 90%) | 60 patients per group |